Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Perindopril,Perindopril Arginine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2024
Lead Product(s) : Perindopril,Perindopril Arginine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perindopril,Indapamide,Amlodipine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : Perindopril,Indapamide,Amlodipine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2023
Lead Product(s) : Clopidogrel,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramipril,Hydrochlorothiazide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Ligand Research, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Ramipril,Hydrochlorothiazide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Ligand Research, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atorvastatin,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Atorvastatin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramipril,Hydrochlorothiazide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Ligand Research, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : Ramipril,Hydrochlorothiazide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Ligand Research, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aceclofenac,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : X7 Clinical Research LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : Aceclofenac,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : X7 Clinical Research LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Torsemide,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : Torsemide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sildenafil Citrate,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2021
Lead Product(s) : Sildenafil Citrate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable